PDF(Pubmed)
Abstract：
UNASSIGNED: Inpatient monitoring is recommended for sotalol initiation.
UNASSIGNED: The purpose of this study was to assess the safety of outpatient sotalol commencement.
UNASSIGNED: This is a multicenter, retrospective, observational study of patients initiated on sotalol in an outpatient setting. Serial electrocardiogram monitoring at day 3, day 7, 1 month, and subsequently as clinically indicated was performed. Corrected QT (QTc) interval and clinical events were evaluated.
UNASSIGNED: Between 2008 and 2023, 880 consecutive patients who were commenced on sotalol were evaluated. Indications were atrial fibrillation/flutter in 87.3% (n = 768), ventricular arrhythmias in 9.9% (n = 87), and other arrhythmias in 2.8% (n = 25). The daily dosage at initiation was 131.0 ± 53.2 mg/d. The QTc interval increased from baseline (431 ± 32 ms) to 444 ± 37 ms (day 3) and 440 ± 33 ms (day 7) after sotalol initiation (P < .001). Within the first week, QTc prolongation led to the discontinuation of sotalol in 4 and dose reduction in 1. No ventricular arrhythmia, syncope, or death was observed during the first week. Dose reduction due to asymptomatic bradycardia occurred in 3 and discontinuation due to dyspnea in 3 within the first week. Overall, 1.1% developed QTc prolongation (>500 ms/>25% from baseline); 4 within 3 days, 1 within 1 week, 4 within 60 days, and 1 after >3 years. Discontinuation of sotalol due to other adverse effects occurred in 41 patients within the first month of therapy.
UNASSIGNED: Sotalol initiation in an outpatient setting with protocolized follow-up is safe, with no recorded sotalol-related mortality, ventricular arrhythmias, or syncope. There was a low incidence of significant QTc prolongation necessitating discontinuation within the first month of treatment. Importantly, we observed a small incidence of late QT prolongation, highlighting the need for vigilant outpatient surveillance of individuals on sotalol.
UNASSIGNED: The purpose of this study was to assess the safety of outpatient sotalol commencement.
UNASSIGNED: This is a multicenter, retrospective, observational study of patients initiated on sotalol in an outpatient setting. Serial electrocardiogram monitoring at day 3, day 7, 1 month, and subsequently as clinically indicated was performed. Corrected QT (QTc) interval and clinical events were evaluated.
UNASSIGNED: Between 2008 and 2023, 880 consecutive patients who were commenced on sotalol were evaluated. Indications were atrial fibrillation/flutter in 87.3% (n = 768), ventricular arrhythmias in 9.9% (n = 87), and other arrhythmias in 2.8% (n = 25). The daily dosage at initiation was 131.0 ± 53.2 mg/d. The QTc interval increased from baseline (431 ± 32 ms) to 444 ± 37 ms (day 3) and 440 ± 33 ms (day 7) after sotalol initiation (P < .001). Within the first week, QTc prolongation led to the discontinuation of sotalol in 4 and dose reduction in 1. No ventricular arrhythmia, syncope, or death was observed during the first week. Dose reduction due to asymptomatic bradycardia occurred in 3 and discontinuation due to dyspnea in 3 within the first week. Overall, 1.1% developed QTc prolongation (>500 ms/>25% from baseline); 4 within 3 days, 1 within 1 week, 4 within 60 days, and 1 after >3 years. Discontinuation of sotalol due to other adverse effects occurred in 41 patients within the first month of therapy.
UNASSIGNED: Sotalol initiation in an outpatient setting with protocolized follow-up is safe, with no recorded sotalol-related mortality, ventricular arrhythmias, or syncope. There was a low incidence of significant QTc prolongation necessitating discontinuation within the first month of treatment. Importantly, we observed a small incidence of late QT prolongation, highlighting the need for vigilant outpatient surveillance of individuals on sotalol.
摘要：
■建议开始进行索他洛尔的住院监护。
■本研究的目的是评估门诊索他洛尔的安全性。
■这是一个多中心，回顾性,在门诊使用索他洛尔的患者的观察性研究。在第3天，第7天，1个月，连续心电图监测，随后进行临床指征。评估校正的QT（QTc）间期和临床事件。
■在2008年至2023年之间，对880名开始服用索他洛尔的连续患者进行了评估。适应症为房颤/扑动，占87.3%（n=768），9.9%(n=87)的室性心律失常，其他心律失常占2.8%(n=25)。起始日剂量为131.0±53.2mg/d。在索他洛尔开始后，QTc间期从基线（431±32ms）增加到444±37ms（第3天）和440±33ms（第7天）（P<.001）。第一周内,QTc延长导致索他洛尔停药4，剂量减少1。没有室性心律失常,晕厥,或在第一周观察到死亡。在第一周内，无症状的心动过缓导致的剂量减少发生在3，而由于呼吸困难导致的停药在3。总的来说,1.1%出现QTc延长(基线>500ms/>25%)；3天内4次，1周内,4在60天内，和1后>3年。在治疗的第一个月内，41名患者因其他不良反应而停用索他洛尔。
■索他洛尔在门诊环境中的初始随访是安全的，没有记录索他洛尔相关死亡率，室性心律失常,或者晕厥.在治疗的第一个月内需要停药的显著QTc延长的发生率较低。重要的是,我们观察到晚期QT延长的发生率较小，强调需要对索他洛尔患者进行警惕的门诊监测。
■本研究的目的是评估门诊索他洛尔的安全性。
■这是一个多中心，回顾性,在门诊使用索他洛尔的患者的观察性研究。在第3天，第7天，1个月，连续心电图监测，随后进行临床指征。评估校正的QT（QTc）间期和临床事件。
■在2008年至2023年之间，对880名开始服用索他洛尔的连续患者进行了评估。适应症为房颤/扑动，占87.3%（n=768），9.9%(n=87)的室性心律失常，其他心律失常占2.8%(n=25)。起始日剂量为131.0±53.2mg/d。在索他洛尔开始后，QTc间期从基线（431±32ms）增加到444±37ms（第3天）和440±33ms（第7天）（P<.001）。第一周内,QTc延长导致索他洛尔停药4，剂量减少1。没有室性心律失常,晕厥,或在第一周观察到死亡。在第一周内，无症状的心动过缓导致的剂量减少发生在3，而由于呼吸困难导致的停药在3。总的来说,1.1%出现QTc延长(基线>500ms/>25%)；3天内4次，1周内,4在60天内，和1后>3年。在治疗的第一个月内，41名患者因其他不良反应而停用索他洛尔。
■索他洛尔在门诊环境中的初始随访是安全的，没有记录索他洛尔相关死亡率，室性心律失常,或者晕厥.在治疗的第一个月内需要停药的显著QTc延长的发生率较低。重要的是,我们观察到晚期QT延长的发生率较小，强调需要对索他洛尔患者进行警惕的门诊监测。
